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Validation of a fornix depth measurer: a putative tool
for the assessment of progressive
cicatrising conjunctivitis
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S John Curnow,1 Peter Nightingale,4 Saaeha Rauz1
ABSTRACT
Background/aims Documentation of conjunctival
forniceal foreshortening in cases of progressive cicatrising
conjunctivitis (PCC) is important in ascertaining disease
stage and progression. Lower fornix shortening is often
documented subjectively or semi-objectively, whereas
upper forniceal obliteration is seldom quantified. Although
tools such as fornix depth measurers (FDMs) have been
described, their designs limit upper fornix measurement.
The purpose of this study was to custom-design a FDM to
evaluate the upper fornix and to assess variability in
gauging fornix depth.
Methods A polymethylmethacrylate FDM was
constructed using industry-standard jewellery computer
software and machinery. Two observers undertook
a prospective independent evaluation of central lower
fornix depth in a heterogeneous cohort of patients with
clinically normal and abnormal conjunctival fornices both
subjectively and by using the FDM (in mm). Upper
central fornix depth was also measured. Agreement was
assessed using BlandeAltman plots.
Results Fifty-one eyes were evaluated. There was 100%
intraobserver agreement to within 1 mm for each
observer for lower fornix measurement. The mean
difference in fornix depth loss using the FDM between
observer 1 and 2 was 1.19%, with 95% confidence of
agreement (62SD) of 15% to +20%. In total, 86%
(44/51) of measurements taken by the two observers
agreed to within 10% of total lower fornix depth (ie,
61 mm) versus only 63% (32/51) of the subjective
measurements. Mean upper fornix difference was
0.57 mm, with 95% confidence of agreement of
between 2 and + 3 mm.
Conclusions This custom-designed FDM is well
tolerated by patients and shows low intraobserver and
interobserver variability. This enables repeatable and
reproducible measurement of upper and lower fornix
depths, facilitating improved rates of detection and
better monitoring of progression of conjunctival scarring.
INTRODUCTION
Sequential documentation of forniceal fore-
shortening in cases of progressive cicatrising
conjunctivitis (PCC), such as ocular mucous
membrane pemphigoid (OcMMP), is important in
assessing stage and progression of disease.1e3 The
Foster staging relies on subjective evaluation of
subepithelial ﬁbrosis and extent of symblepharon
formation,3 and the system described by Mondino
and Brown2 4 describes grading of percentage
shrinkage of the lower fornix. A modiﬁcation
encompassing both systems was described by
Tauber et al,1 who proposed that counting the
number of, and percentage horizontal obliteration
of the lower fornix by symblephara could potentially
improve detection of disease progression.
We have previously shown that lower fornix
shortening is documented either subjectively or
semi-objectively by utilising a slit-light beam, the
degree of upper forniceal obliteration is seldom
quantiﬁed.5 Furthermore, we have shown that, at
the initial visit to tertiary referral centres, Foster ’s
staging of disease is undertaken in 100% of
patients’ lower fornix, but only 78% of patients had
quantiﬁcation of forniceal shrinkage. This is prob-
ably related to the difﬁculty in assessing lower
fornix depth accurately without the aid of a made-
for-purpose tool.6
Measurement of the fornices using devices such
as the fornix depth measurer (FDM) has previously
been described, but their design restricts accurate
upper fornix measurements.7 8 Speciﬁcally, the
depth and curvature of the upper fornix dictates
that the ideal FDM must be sufﬁciently long and
curved to enable comfortable and accurate assess-
ment of it. We previously used in routine clinical
practice an FDM based on that designed by Schwab
et al,7 but its design was suboptimal (ﬁgure 1). In
2004, a modiﬁcation of the Schwab FDM was
designed at Moorﬁelds Eye Hospital for a clinical
trial9 and is currently being used in an epidemio-
logical study. In 2007, we wanted to redesign and
evaluate a bespoke comfortable prototype that
could provide an accurate tool for improving
forniceal sac documentation in the outpatient clinic
setting, with potential for wider-scale commercial
manufacture. In this study we describe this
custom-designed FDM constructed speciﬁcally to
facilitate evaluation of the depth of the upper
conjunctival fornix, and we assess intraobserver
and interobserver variability in gauging the extent
of the upper and lower fornices by validating the
FDM and comparing it with subjective assessment
of fornix shrinkage.
MATERIALS AND METHODS
Design of a bespoke FDM
Apolymethylmethacrylate FDMwasdesignedusing
industry-standard jewellery computer software
(CAD V5, 3Design, Brussieu, France, 2007). The
virtual model was then exported as an. STL ﬁle into
a program to set the cutting parameters for the
milling machine (Modela Player V4; Roland DG,
Shizuoka, Japan, 2002) (ﬁgure 2A).The virtualmodel
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was cut with a machine to a precision of 2 mm/step, and incre-
ments were expressed at 2 mm intervals at both ends of the FDM:
the main ‘body ’ and the ‘handle’. This design feature enables
measurement of the fornix in the context of multiple symble-
phara, which could potentially hinder the smooth passage of the
FDM to the limits of the conjunctival sac. The FDM measured
25 mm3 5 mm and was moulded to a biconcave shape to ensure
ease of insertion and comfort (ﬁgures 1C and 2B).
Patients
An evaluation of the bespoke FDM was undertaken through
a prospective, masked, independent assessment of central lower
fornix depth by two observers (GPW, TS), following the Tenets
of the Declaration of Helsinki. This was undertaken as a service
evaluation at the Birmingham and Midland Eye Centre (BMEC).
The validation of the FDM was conducted on a heterogeneous
group of patients comprising clinically normal and abnormal
conjunctival fornices presenting to BMEC. This heterogeneity
enabled a wide range of fornix depths to be tested with the
bespoke FDM.
The cohort consisted of 51 eyes of 26 patientswith amedian age
of 64 years (range 42e100), of whom 65% (17/26; 33/51 eyes) had
an identiﬁable cause of cicatrising conjunctivitis (OcMMP, 10; dry
eyes, ﬁve (including three with Sjögren’s syndrome); Stevense
Johnson syndrome, two) and 35% (18/51) had no evidence of
conjunctival scarring (age-related macular degeneration, four;
uveitis, three; peripheral ulcerative sclerokeratitis, two).
After instillation of one drop of 0.4% oxybuprocaine hydro-
chloride, patients were asked to look in the opposite direction to
the placement of the FDM (upper fornix, down-gaze; lower
fornix, up-gaze) in order to protect the cornea, ensure consis-
tency in readings, and circumvent variability in the eyelid
position in primary gaze. The central conjunctival fornix was
measured to the eyelid margin, deﬁned as the posterior lip of the
meibomian gland oriﬁce (ﬁgure 1C). All FDM readings were
taken in triplicate, with the ﬁrst measurement taken used for
interobserver comparison. A semi-objective estimation of lower
fornix conjunctival shrinkage was also performed by gauging the
central lower fornix depth, measured from the inferior fornix to
the eyelid margin with the aid of a vertical 1 mm wide slit-lamp
beamwith illumination and observation axes in a coaxial position
(NB a subjective assessment of the upper fornix is impossible).
The FDM was sterilised by soaking the device in 0.05% sodium
dichloroisocyanurate solution for 5 min between patients (as per
the BMEC infection control policy for reusable tonometer heads).
Patients were also asked about their tolerance to the FDM.
Calculations and statistical analyses
The percentage loss of lower fornix for both methods of
measurement (subjective and objective) was calculated using the
equation:
f½fornix depth ðFDÞ age  FDM measurement=FD ageg 3100
¼ % loss of fornix
A correction factor for age was implemented, as the lower
forniceal depth is known to progressively shorten with age.7 The
‘FD age’ values were derived from published age-speciﬁc lower
fornix depths in normal eyes detailed in table 1.7 For example,
Figure 1 Colour photographs
illustrating the evolution of the fornix
depth measurer (FDM). (A) The original
adaptation of an FDM described by
Schwab et al7 (produced by our local
prosthetics department). (B) An FDM
constructed at Moorfields Eye Hospital,
which is an elongated
polymethylmethacrylate modification of
the Schwab FDM using a hand-made
plaster cast (designed by VS, Scott Hau
and David Carpenter, ocular prosthetist
at Moorfields Eye Hospital, specifically
to facilitate upper fornix depth
measurement for use in a clinical trial).
For comparison, (C) illustrates the
computer-designed bespoke FDM
prototype. This is an elongated,
biconcave design with engraved
markings to a precision of 2 mm/step,
and increments expressed at 2 mm
intervals on both the main body of the
FDM and the narrower ‘handle’. The
markings on the handle facilitate upper
fornix measurement and the ability to
measure the fornix in the presence of
symblephara (D). The accuracy and
reproducibility of the computer-
generated design and jewellery
precision engraving provides potential
for commercial manufacture.
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for a patient aged 80 years with a lower fornix measurement of
6 mm, the calculated percentage shrinkage is as follows:
f½10:2 6=10:23100g ¼ 41:2%
It is important to note that it was not possible to calculate
percentage loss of the upper fornix because the normal range of
age-speciﬁc upper forniceal depths is currently unknown.
Intraobserver and interobserver agreement was assessed using
BlandeAltman plots of differences in measurements versus
mean measurements using Excel for Macintosh (Microsoft
Ofﬁce 2008).10 11 The mean difference in observations and the
95% limits of agreement (the mean difference 62 standard
deviations)10 were calculated using SPSS V16.0 for Macintosh. A
continuity correction was applied to the 95% limits of agree-
ment to take account of the fact that BlandeAltman plots
assume that the variables measured are continuous.
A 10% threshold or ‘tolerance’ was chosen as an allowance for
intraobserver variation. Agreement was also evaluated by
determining the percentage of observations that agreed to
within the 10% ‘allowance’ for both observers.
RESULTS
Lower fornix assessment
Intraobserver variation
Triplicate measurements of FDM readings of the same
anatomical position by each observer (central lower fornix)
showed exact agreement of 86% (42/49) and 89% (41/46) of
measurements within observer 1 and observer 2, respectively.
When allowing for 1 mm ‘tolerance’ (approximating to 10% of
the normal lower fornix, see table 1), 100% of intraobserver
observations fell within 1 mm for both observers.
Interobserver variation
Interobserver variation between the subjective and objective
measurements of the central lower fornix by the two observers
was also assessed. Assessment of the lower fornix shrinkage was
expressed as a percentage for both subjective and objective
estimations, the latter using the age correction factor described
in the methods.7
Figure 2 (A) A
polymethylmethacrylate fornix depth
measurer (FDM) was constructed using
industry-standard jewellery software
and machinery. A screenshot of the
3design prototype is shown in (A). The
final prototype is illustrated in (B).
Increments are expressed at 2 mm
intervals to a precision of 2 mm/step,
and the FDM was heat moulded to
a biconcave shape for comfort. The FDM
was applied after instillation of one drop
of 0.4% oxybuprocaine hydrochloride
(C). Patients were asked to look in the
opposite direction to the placement of
the FDM, and the central conjunctival
fornix was measured to the eyelid
margin, defined as the posterior lip of
the meibomian gland orifice.
Table 1 Age-specific normal values for the conjunctival
lower fornix
Age
Mean depth of
normal lower
fornix (mm) (‘100%’)
10% of normal
lower fornix (mm)
40e49 11.9 1.19
50e59 11.3 1.13
60e69 11.0 1.10
70e79 10.6 1.06
80+ 10.2 1.02
Adapted from Schwab et al.7
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The mean difference in calculated percentage fornix depth
using measurements obtained from the FDM by observer 1 and
2 was 1.19%, and, with a continuity correction, the 95% limits
of agreement (62SD) were narrower for interobserver objective
(FDM) measurements than for those obtained subjectively
(15% and + 20%) (ﬁgure 3). The interobserver agreement
within the 10% allowance (ie, approximately 61 mm) of total
lower fornix depth was 86% (44/51) (ﬁgure 4).
In contrast, the interobserver mean difference in subjective
estimation of percentage fornix depth was 1.86%, and, with
a continuity correction, the 95% limits of agreements (62 SD)
were between 30% and +25% (ﬁgure 3). Only 63% (32/51)
of the subjective measurements taken by the two observers
agreed to within a 10% allowance of total lower fornix depth
(ﬁgure 4).
These data highlight that the FDM afforded greater consis-
tency in fornix depth measurement by each observer (intra-
observer variation) and between observers (interobserver
variation).
Upper fornix assessment
Intraobserver variation
Triplicate measurements (to assess intraobserver variation) of
FDM readings of the same anatomical position of the central
upper fornix by each observer showed minimal variation (ie,
identical objective measurements) in 88% (45/51) and 70%
(33/47) of measurements by observer 1 and observer 2, respec-
tively. There are no data regarding normal upper fornix depth in
the published literature, preventing calculations for age-based
corrections and percentage fornix depth foreshortening and
tolerance threshold.
Interobserver variation
Interobserver variation of the upper fornix showed a mean
difference in fornix depth measurement using the FDM for
observer 1 and 2 of 0.57 mm, with 95% limits of agreement
(62SD) of 2 and + 3 mm (ﬁgure 5). The absence of normal
upper fornix values precludes evaluation of the 10% allowance;
however, 84.3% (43/51) of upper fornix measurements were
within 1SD of the mean difference of 0.57 mm (+2 to 1 mm of
the mean with a continuity correction).
Patient comfort and tolerance
The FDM was well tolerated by patients, with only a few
(three) experiencing mild discomfort during upper fornix
measurement, despite repeated measurements. None of these
patients reported prolonged discomfort or pain.
DISCUSSION
PCC comprises a group of disorders characterised by progressive
scar formation in response to conjunctival inﬂammation
affecting the stromal layers of the conjunctiva.12 These include
ocular immunobullous diseases such as OcMMP, Stevense
Johnson syndrome and toxic epidermal necrolysis, lichen planus,
linear IgA disease, paraneoplastic pemphigus and epidermolysis
bullosa. Other causes include graft-versus-host disease, Sjögren’s
syndrome, acne rosacea and those associated with topical
therapy where progression is reported to be more insidious with
less destructive clinical sequelae.
Because of the sight-threatening consequences of OcMMP, the
ocular phenotype of MMP is regarded as ‘high risk’,13 particu-
larly as disease progression is more aggressive in younger
Figure 3 BlandeAltman plots showing
interobserver variation in lower fornix
assessment ((A) objective and (C)
subjective). Some data points are
identical and therefore overlay each
other on the figures. The percentage
difference in assessment between
observer 1 and 2 is plotted against the
mean percentage loss of fornix for each
eye. If there was a completely normal
fornix, this is represented as 0% loss of
fornix on the x axis. Note the increase in
the 95% limits of agreement (62SD) for
subjective assessment (arrowed),
demonstrated also by the histograms
(B,D).
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patients14 and 50% of patients continue to have progression of
cicatrising disease in the apparent absence of inﬂammation.15
Determining progression in PCC is a challenging aspect of
patient management. When considering OcMMP, for example,
the most common of the acquired immunobullous diseases that
cause PCC,12 16 progression may occur at any stage of disease,2 17
which can be aggressive early in the disease course,14 but,
importantly, is often independent of clinically identiﬁable
inﬂammation.15 Determining disease progression in the cica-
trising conjunctivitides therefore relies upon accurate docu-
mentation of disease, in particular conjunctival shrinkage of the
fornices. Although the Mondino staging system is considered to
be more sensitive than Foster ’s staging system15 and is inte-
grated into the system proposed by Tauber et al,1 Mondino
fornix depth measurement is reported to be undertaken in only
78% of new patients in tertiary referral centres compared with
100% documentation of the Foster ’s system.
Vigilant assessment, quantiﬁcation and documentation of
forniceal foreshortening is mandatory for enabling accurate
patient follow-up, currently not achieved by subjective or semi-
objective assessments of the fornix. These approaches are
limited by inconsistency and poor reproducibility and reliability,
but are overcome by the development and implementation of
fornix depth measuring devices for the assessment and
progression of diseases that cause conjunctival scarring.7 8 18 Our
aim was to design an FDM based upon the original concept of
Schwab et al,7 but with additional upper fornix depth capability.
Speciﬁcally, our custom-made FDM was found to be comfort-
able and accurate. Designed and made using industry-standard
computer software and machinery, this FDM prototype was
modelled mathematically taking into account the curvature of
the globe necessary for comfortable measurement of the upper
fornix. We tested our bespoke FDM on patients with a range of
fornix depths in the presence or absence of conjunctival ﬁbrosis.
Our ﬁndings showed low intraobserver and interobserver vari-
ability, enabling repeatable and reproducible measurements of
both upper and lower fornix depths, highlighting its potential in
facilitating both accurate and robust clinical documentation of
disease stage. This FDM prototype is currently being optimised
with further modiﬁcations to improve comfort and ﬁt.
Crucially, the conjunctival cicatrising process is not conﬁned
to the lower fornix, and sight-threatening sequelae secondary to
subtarsal ﬁbrosis, upper lid entropion or lash trauma commonly
ensue. These clinicopathological processes are not taken into
Figure 4 Difference in objective (A) and subjective (B) lower fornix
assessment between observer 1 and 2. The number of individuals that
agree to within a 10% ‘allowance’ are boxed and are higher for objective
measurements (86% (44/51)) than for subjective measurements (63%
(32/51)).
Figure 5 (A) BlandeAltman plot showing interobserver variation in upper fornix assessment. As there are no defined limits for the upper fornix, the
calculations are in mm. The mm difference in assessment between observer 1 and 2 is plotted against mean mm measurement for each patient. The
95% limits of agreement are vertically arrowed and also represented by a histogram (B). (C) Difference in upper fornix assessment between observer 1
and 2; the 10% allowance cannot be calculated in the absence of normal upper fornix values, but 71% (36/51) of measurements were within 1 mm, and
92% (47/51) of observations were within 2 mm of each other.
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consideration by ocular staging systems that calculate
percentage obliteration of the lower fornix,1 2 4 although are
reﬂected in the staging system described by Foster where fornix
shortening or symblephara of any degree throughout the
conjunctival surface are thought to be important.3 The
decreased sensitivity in relying solely upon this system, or those
that include direct measurement of the lower fornix alone,
increase the risk of type 2 errors (false negatives) in determining
disease progression, which are considerably rescinded by the use
of fornix depth measuring devices for the upper fornix.
The larger depth of the upper fornix and difﬁculty of access
explains the omission of detailed upper fornix pathology in
currently recognised scoring systems.1 2 4 Perhaps not surpris-
ingly therefore, there appear to be few data in the ophthalmic
literature regarding the anthropology and normal depth of the
upper fornix. Kawakita and colleagues8 have recently discussed
the use of a non-curved 15032 mm FDM in Japanese patients
with StevenseJohnson syndrome and healthy volunteers. They
found that the mean superotemporal and superonasal upper
fornix depths were 14.162.5 mm in normal people. Our ﬁndings
show a median central upper fornix depth of 16 mm in
a caucasian group of patients, even in the presence of recognised
cases of cicatrising conjunctivitis. The variation in central upper
fornix depth among healthy populations using anthropological
ethnography together with differences in age remains unre-
solved. This has recently been highlighted in the context of
other diseases affecting the size of the upper fornix such as the
giant fornix syndrome described by Rose.19 These data illustrate
the need for population-based studies of normal age-based upper
fornix depths to facilitate calculations of percentage shrinkage in
conjunctival scarring diseases. Such studies are currently being
undertaken at BMEC and Moorﬁelds Eye Hospital.
In summary, our custom-designed FDM was well tolerated by
patients in this study, with only three experiencing short-lived
mild discomfort during assessment of the upper fornix. This
FDM shows low intraobserver and interobserver variability,
enabling repeatable and reproducible measurements of lower
fornix depths. We believe that the custom design of an FDM
using industry-standard jewellery software and machinery,
curved to ﬁt the globe, provides an accurate and comfortable
means of assessing lower fornix depth. Furthermore, it offers the
potential to measure upper fornix depth, currently not routinely
carried out in clinical practice, thereby improving both the
detection and monitoring of progressive conjunctival ﬁbrosis in
this group of devastating disorders.
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